Chris De Savi is Vice President and Head of Drug Discovery at Kymera Therapeutics. Kymera Therapeutics is a biopharmaceutical company developing novel protein degrader therapeutics to selectively degrade disease causing proteins with the goal of completely removing them from the body. Chris’ team contributes to all drug discovery phases at Kymera from project inception through to clinical candidate discovery and beyond.